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Abstract
The field of ovarian cancer research is undergoing major re-examination. Pathologists
are defining the disease in new terms, and—having observed discrepancies in its
actual cell(s) and tissue(s) of origin—are asking whether or not ovarian cancer truly
represents one disease or a complex group of diseases. Further complexity was
unveiled after sequencing a large number of high-grade serous ovarian cancer tumor
samples (the most frequent ovarian cancer histotype). The experiments uncovered the
existence of at least four different molecular subtypes, which standard pathological
assessment cannot determine. These discoveries propelled a need for designing novel
model systems to study the disease and to develop therapies tailored to the molecular
genetics of the tumor. Though there has been no major breakthrough as regards
overall patient survival of ovarian cancer in the last 50 years, this chapter summarizes
the many challenges and fascinating opportunities scientists face in altering the fatal
course of this disease.
Keywords: Epithelial ovarian cancer (EOC), the cancer genome atlas (TCGA), pa‐
tient-derived xenografts (PDXs), peritoneal ovarian carcinomatosis, tumor burden,
tumor dormancy, minimal residual disease (MRD), high-grade serous ovarian can‐
cer (HGSOC), Genetically engineered mouse models (GEMM), single nucleotide
polymorphisms (SNPs), Calculator of Ovarian Carcinoma Subtype Prediction
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1. Introduction
1.1. Ovarian cancer represents various diseases
Epithelial ovarian cancer (EOC) is the deadliest gynecological disease. Over 70% of patients
are diagnosed at late stages when the disease has disseminated within the abdominopelvic
cavity. This is due to a lack of specific symptoms and valid biomarkers to look out for in early
screenings, a consequence of the poor understanding of the disease’s pathobiology. Upon late
diagnosis, the standardized treatment is surgery (to remove all macroscopic disease within the
abdominal cavity), followed by 6 cycles of a platinating, DNA-damaging agent combined with
a taxane that disrupts microtubule function. Ninety percent of patients with late diagnosis,
despite showing a promising initial response to standard of care treatment, ultimately relapse
and die of the disease. The 5-year survival rate for EOC has remained below 35% over the past
20 years (rev.in [1-6]).
EOC genetically and biologically represents various diseases with different sites of origin that
share common anatomical locations in the abdominal cavity when symptomatic [6]. EOCs are
histologically classified as low-grade serous carcinoma, endometrioid carcinoma, clear-cell
carcinoma, mucinous carcinoma, and high-grade serous ovarian carcinoma (HGSOC) [4].
Mucinous ovarian tumors are frequently the result of metastatic gastrointestinal cancers. Clear
ovarian cancers and endometrioid ovarian cancers likely originate from endometrioid lesions,
whereas serous ovarian cancers have 3 likely sites of origin: (1) the secretory cells of the distal
fallopian tubes, (2) the ovarian surface epithelium, and (3) a niche of cells found in the hilum
region of the ovary in a transitional area among the ovarian surface epithelium, the mesothe‐
lium, and the tubal epithelium [7, 8]. Among serous ovarian cancers, the low-grade serous
tumors often carry wild-type p53 gene, are chromosomally stable and frequently unresponsive
to platinum therapy, and carry Ras mutations. In contrast, HGSOC are p53 mutant and usually
highly responsive to platinum therapy, and carry widespread DNA copy changes and wild-
type Ras [9].
HGSOC is the most aggressive subtype of EOC, represents the majority of cases of EOC, and
causes almost 70% of all deaths from this disease [9]. The Cancer Genome Atlas (TCGA)
network reported the genetic sequencing of 489 tumors histopathologically classified as
HGSOC [10]. The study confirmed, in a larger cohort of patients, that the genetic signature of
HGSOC involves mutation of tumor suppressor p53 in 96-97% of cases, as previously described
in a smaller cohort [11], with almost 50% of the tumors having dysregulation of the homolo‐
gous recombination DNA repair pathway. The study led to revisiting HGSOC in terms of its
biology, response to chemotherapy, clinical outcome, and genetic subtypes [6, 9, 12].
2. There are insufficient model systems to study ovarian cancer in vivo
The stagnation in successfully treating patients with EOC is compounded with an insufficiency
of model systems to study the disease when harbored within the abdominopelvic cavity. Four
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main approaches have been used to study EOC in vivo in mice: (1) genetically engineered
mouse models (GEMM) that develop EOC from the epithelium of the ovaries [13-15] or the
oviducts (fallopian tubes) [16, 17]; (2) syngeneic models in which mouse EOC cells are
orthotopically xenografted into the ovarian bursa [18] or the peritoneal cavity [19] of immu‐
nocompetent mice; (3) patient-derived xenografts (PDX) models in which the tumors of the
patients are transplanted into the peritoneal cavity of severe immunodeficient mice (deficient
in T-cells, B-cells and NK cells) [20-22]); and (4) xenografts of human EOC cells into the flanks
or the abdominal cavity of nude, T-cell deficient mice [23]. Current GEMM of EOC facilitate
studying the disease from its inception. Yet, due to a lack of highly specific promoters to target
the presumed cells of origin, the GEMM do not develop the same genetic lesions carried by
patients, and, hence, do not recapitulate the human phenotype in its entirety (rev.in [24, 25]).
The use of mouse EOC cells xenografted in immunocompetent mice is highly relevant since
the disease can be assessed in the presence of an intact immune system; however, the number
of available models is limited [18, 19]. PDX closely recapitulate the histology of the patient's
sample when placed within the peritoneal cavity as a finely minced tumor with some varia‐
bility depending on the host mice. For instance, when human ovarian cancer tissues are
xenografted in SCID (C.B-17/IcrHsd-Prkdcscid Lystbg) mice, the human stroma accompanying
the cancer cells is rapidly replaced with mouse stroma [22]. In contrast, in severe immunode‐
ficient NOD-SCID IL2Rγnull (NSG) mice lacking acquired and innate immunities [26], the tumor
associated human stromal cells (e.g. fibroblasts and lymphocytes) remain functional for an
extended period of time [20]. Nevertheless, the xenograft of EOC into the peritoneal cavity of
immunosuppressed mice recapitulates only a late phase of disease as the cells are directly
deposited into the peritoneal cavity of a host. Clearly, each model system for recapitulating
EOC in mouse models has shortcomings.
3. The progression of epithelial ovarian cancer within the abdominopelvic
cavity is not easy to assess
Studies involving the implantation of EOC cells in the peritoneal cavity (intraperitoneally; i.p.)
of host mice are limited when compared to the number of studies done using EOC cells
xenografted subcutaneously (s.c.) (rev.in [25, 27]). One main reason for this discrepancy is that
the growth of s.c. tumors can be monitored easily using precision calipers; yet, this site fails to
represent the environment of the abdominal cavity in which EOC thrive. The struggle to
analyze disease progression in the peritoneal cavity is that it requires sophisticated, non-
invasive, imaging approaches to follow the development of internal tumor nodules in a context
of a lack of well-defined parameters of tumor burden [28]. In most studies done with i.p.
xenografts, tumor burden has been assessed by recording overall survival [23], noting volume
of ascites accumulated [29], or calculating the total mass of what is considered tumoral tissue
after collection from the abdominal cavity at necropsy [30]. More recently, non-invasive
imaging methods to evaluate tumor progression in longitudinal studies have been developed,
yet their application in evaluating EOC within the peritoneal cavity has been limited [25].
Overall, information as to how EOC develops within the abdominal cavity is scarce. Preferred
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sites of anatomical distribution of the tumors remain unknown as do their histopathology and
molecular genetics.
4. Peritoneal ovarian cancer needs to be studied in different regions of the
abdominopelvic cavity
It is feasible that solid nodules that develop, for instance, in the omentum, have a different
genetic profile when compared with sibling nodules found in other sites, such as the dia‐
phragm, the surface of the liver, the bowel, or the lower pelvic cavity. This might be due to
tissues (to which each tumor foci must adapt) having different histological and physiological
micro-environments, likely impinging on the behavior of the cancer cells. Depending on the
nearby tissue microenvironment, cancer cells may hijack otherwise non-malignant cells in a
different manner depending on the anatomical location of the foci. As a consequence, this
differential tumor adaptation to the environment may explain the apparent heterogeneity
observed in tumors found within the peritoneal cavity of patients at the moment of debulking
surgery, sometimes leading to difficulties in making the correct histopathological diagnosis of
the overall disease. Thus, there is an urgent need to (1) standardize, across a genetically-defined
group of available EOC cell lines, a common set of histopathological and genetic biomarkers
of disease growing in the abdominal cavity; and (2) determine if such biomarkers, despite being
expressed from the same cell types of origin, show heterogeneity according to the site within
the abdominal cavity where the tumor develops. For instance, evidence suggests that omental
vs. ovarian sites of HGSOC patients show variability in the host stromal responses among the
sites [31]. Another study using biopsies from different sites within the peritoneal cavity of
patients with HGSOC show heterogeneity or clonal diversity among the tumor sites mani‐
fested by single nucleotide polymorphisms (SNPs) associated with differentially expressed
genes [32].
One tool currently available for characterizing the histopathological subtype of ovarian
carcinomas is the Calculator of Ovarian Carcinoma Subtype Prediction (COSP), which is an
algorithm that encompasses 9 predictive biomarkers and is used to differentiate histotypes of
EOCs. The algorithm is freely accessible [33] and permits the scoring by immunohistochem‐
istry, using standardized antibodies and incubation procedures, the abundances of WT1
(Wilms Tumor 1), p16 (cyclin dependent kinase inhibitor 2A; CDKN2A), DKK1 (dickkopf
homolog 1), VIM (vimentin), p53 (TP53), PRG (progesterone receptor), TFF3 (trefoil factor 3
[intestinal]), HNF1B (hepatocyte nuclear factor 1β) and MDM2 (mouse double minute 2). The
scores for these markers are 0 or 1, except for p53 that has scores of 0 (no expression denoting
null p53), 1 (low abundance for wild type p53), or 2 (high abundance for mutant p53). For
instance, for the Kuramochi ovarian cancer cell line (see later Table 1), the algorithm predicts
a HGSOC histotype with 97% probability, whereas for the popular A2780 ovarian cancer cell
line (see later Fig.1), the algorithm predicts an endometrioid histotype with 94% probability
[34]. A limitation to the algorithm is its difficulty in clearly differentiating between low-grade
and high-grade serous histotypes. However, low-grade serous ovarian carcinomas only
account for ~3% of all [35]. Furthermore, a combination of histological assessment and
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molecular genetic profiles should be able to distinguish between these two serous ovarian
cancer subtypes.
5. Most popular epithelial ovarian cancer cell lines used to study peritoneal
carcinomatosis in mouse models give rise to disparate intra-abdominal
disease phenotypes
Common EOC cell lines, utilized for years in preclinical studies, were evaluated for their ability
to cause i.p. tumors [23]. ES-2, A2780, and HEY cells (all originally diagnosed as undifferen‐
tiated carcinomas), OV2008 (likely originated from an endometrial carcinoma), and SKOV-3
(which depicts a clear-cell adenocarcinoma histotype in xenografts) all develop intra-abdomi‐
nal tumors in less than 3 months. The tumors are described as “dense solid,” often accompanied
by accumulation of cellular ascites. Our experience with widely used EOC cell lines reveals
different times for the establishment of the xenografts and highly diverse anatomical depiction
of the solid growths within the abdominal cavity among the different cell lines. IGROV-1 cells
generate large solid masses termed omental cakes that expand toward the lower pelvic cavity
(Fig.1A). SKOV-3 cells develop small yet multiple nodules in the mesentery and the omentum
(Fig.1B), while A2780 cells develop large solid masses, taking the ovaries and the lower pelvic
cavity (Fig.1C). The diversity in anatomical growths is likely due to the varied histotypes and
genetic profiles represented by these cell lines (see later) [36].
Figure 1. Peritoneal disease caused by IGROV-1 (A), SKOV-3 (B), and A2780 (C) EOC cells. The images were taken
after 4 weeks of injection for IGROV-1, 10 weeks for SKOV-3, and 6 weeks for A2780 tumors. In A, the growth within
the peritoneal cavity is mostly confined to an “omental cake” (white area). In B, dotted black areas show solid tumors
adhering to fat in the pelvic region, intestines, and mesentery. In C, right (ROT) and left (LOT) ovarian tumors clearly
are connected to the uterine horns (yellow arrows). Ovaries carrying tumors have more blood supply and are larger
than the rest of the peritoneal, pale nodules (yellow pattern).
6. The majority of epithelial ovarian cancer cell lines used for preclinical
studies do not embody the most frequent histotype of the disease
Based on the genetic signatures published from over 50 human ovarian cancer cell lines widely
available, out of the approximately 100 that have been described in the literature [36-38], it is
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apparent that the vast majority of the cell lines overwhelmingly used for over 30 years to study
the disease have a genotype which does not resemble the most predominant histotype of EOC,
HGSOCs. This may be a major contributing factor in the failure to bring new and effective
treatments of HGSOC to clinical practice.
The cell lines currently characterized as likely representing HGSOC [36-38] were developed
in the 1970s and 1980s and have been poorly described. Oftentimes they lack information on
the original histopathological diagnosis, are poorly linked to patient data, and were developed
from ascites or solid nodules following an array of protocols not always clearly stated. It is
imperative that biomedical researchers worldwide join efforts to develop new, highly stand‐
ardized and annotated ovarian cancer cell lines. These cells lines should be developed under
similar isolation and culture protocols as to prevent inter-laboratory variations in their
behavior, thus accelerating the creation of new knowledge in the field of preclinical ovarian
cancer modelling and therapy. By taking advantage of the progress made in the area of
molecular genetics and ovarian cancer biology, it is time to generate new cell lines that
genetically and histopathologically can be characterized as pertaining, for instance, to the
HGSOC histotype, and, within it, to each one of the molecular subtypes described by Tothill
et al. [39] and later on confirmed in a larger cohort of patients [10]. Additionally, there is a
timely opportunity to utilize these biological resources with the objective of standardizing
mouse models of intra-abdominal disease caused by genetically-identified HGSOC cells.
7. The need for an expanded definition of tumor burden when referring to
peritoneal ovarian cancer carcinomatosis
Limiting preclinical analysis of tumor burden to overall survival, tumor mass, or volume of
ascites accumulated is not sufficient if we are to find early metrics of response to new therapies
as well as early signs and symptoms of the disease. Re-defining tumor burden in peritoneal
ovarian cancer in a comprehensive manner should provide investigators worldwide with
multifaceted metrics—anatomical, physiological, and behavioral—to be followed to under‐
stand the biology of the progression of EOC and, most importantly, that of the most frequent
HGSOC type. The metrics should also allow inter-laboratory and inter-cell line comparisons
of HGSOC as a unique disease, provide standardized benchmarks for testing new preclinical
therapies, reveal markers of disease state with clinical implications for earlier diagnosis, and
provide a baseline reference for the validation of new HGSOC cell lines established from
patients with well-documented medical history and annotated histopathological diagnosis of
HGSOC.
Based on recently published genotypes [36-38], it is feasible to begin redefining peritoneal
ovarian tumor burden by utilizing the currently available cell lines that have the highest
probability of genetically representing HGSOC (some examples are displayed in Table 1).
Despite that each cell line was established using different culture conditions, we should
standardize all cell lines to grow under the same culture conditions to avoid bias and proceed
to authenticate them using DNA microsatellite short tandem repeats (STR) as recently
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recommended [37]. Only cell lines which match their STR public genetic database 90-100%
should be used worldwide [40]. Validated cell lines may be injected i.p. in the lower pelvic
region of widely available immunosuppressed female mice lacking T-cell function (Hsd:
Athymic Nude-Foxn1nu) or in severe immunodeficient NOD/SCID/IL2Rγnull mice lacking
acquired and innate immunities [26]. Disease progression can then be followed and the signs
and symptoms contrasted against non-cancerous, age-matched controls studied in parallel.
The animals can be monitored to record body weight, abdominal circumference, body
temperature, and food/water intake to build a clinical history of each animal as the disease
progresses, using biomarkers of tumor progression [41]. The experimental animals and age-
matched, non-cancer controls also can be subjected to a battery of behavioral tests to assess
visceral pain, motor function, and depression-like behavior (helplessness and social with‐
drawal). In animal models of EOC, depressive-like behaviors may be facilitated by the
production of inflammatory cytokines from the cancer cells acting at the level of brain regions
like the hippocampus [42, 43] and thus, may be a sensitive marker of disease state. Finally,
these parameters can be completed with longitudinal, intra-abdominal anatomy of the tumor-
carrying mice using non-invasive imaging approaches (e.g. micro-ultrasound) [44, 45]. The
recorded images can then be analyzed longitudinally to identify the formation and progression
of intra-abdominal solid masses and accumulation of ascites fluid. On selected masses, it is
also possible to study vascularity using 3D power Doppler ultrasound [46, 47].
Cell Line Original Histological Classification
KURAMOCHI* undifferentiated
OVSAHO* serous
SNU119* serous
COV362* endometrioid
OVCAR4* undifferentiated
COV318*† serous
JHOS4*† serous
PEO1**† serous
PEO4**† serous
PEO6** serous
PEO14**† serous
TO14** serous
PEO23**† serous
PEA1**† serous
PEA2**† serous
* [36]; ** [38]; † [37].
Table 1. Epithelial ovarian cancer cell lines with likely HGSOC genomic classification.
The accumulation of bloody ascites in the abdominopelvic cavity suggests that changes in
vascular integrity, with possible effects on blood pressure and oxygen delivered, are taking
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place. Indeed, declines in oxygenation and blood pressure have been suggested as biomarkers
of peritoneal tumor progression [28]. Thus, as part of a comprehensive approach for assessing
tumor burden, we suggest determining the level of peripheral blood oxygen saturation [48]
and blood pressure [49]. Finally, we propose completing the assessment of tumor burden by
taking a blood sample from the animals in order to (1) measure cancer antigen CA-125 used
as a biomarker of EOC disease progression [50]; (2) study hematological parameters that can
be altered due to tumor burden—e.g. red and white blood cell counts, platelets, hemoglobin
concentration, and hematocrit; (3) perform chemical analysis of GOT (glutamic oxaloacetic
transaminase) and GPT (glutamic pyruvic transaminase) as surrogate markers of hepatic
function; (4) measure serum levels of creatinine and urea as surrogate markers of renal
function; and (5) measure serum levels of estradiol and progesterone, since they impact the
outcome of the behavioral tests suggested above.
8. Understanding all cellular components of advanced disease
In ovarian cancer, metastasis through the vasculature is rare and a very late manifestation of
the disease. Instead, ovarian cancer cells are prone to spread by direct extension from the
ovaries to adjacent tissues, or to detach from the primary ovarian tumor directly into the
peritoneal cavity where they seed the mesothelium of the omentum, diaphragm, bowel serosa,
and the entire peritoneum [51-53]. Widespread visceral and intestinal wall metastases with
formation of adhesions between the loops of the bowel cause intestinal obstruction, prevent
normal nutrition, and become a primary cause of death [1].
The high incidence (65%) of peritoneal malignant effusions in ovarian cancer patients at
advanced presentation [54, 55], and the development of symptoms due to ascites accumulation
at diagnosis as well as recurrence [56], suggest that the “liquid” component is an active
pathogenic manifestation of the disease. Ovarian cancer cells isolated from peritoneal ascites
of major ovarian cancer histological types were described as organized structures of different
sizes and heterogeneous morphology [57]. Furthermore, multicellular structures isolated
directly from ascites were shown capable of adhering ex vivo to components of the extracel‐
lular matrix and to monolayers of mesothelial cells, suggesting their participation in the
dissemination of ovarian cancer [58]. Cancer cells isolated from ascites and metastatic secon‐
dary sites exhibit a higher percentage of stemness markers when compared to their primary
tumors [59-61]. Additionally, cancer-associated proteins and mRNAs are differentially
expressed in peritoneal effusions when compared to primary carcinomas or solid metastases.
Lastly, there is a differential gene expression among peritoneal effusions when comparing
samples at diagnosis (pre-chemotherapy) vs. samples at recurrence (post-chemotherapy) [62].
Altogether, these data suggest that cancer cells within effusions—the “liquid” component of
ovarian cancer—represent a biomarker of tumor evolution toward a more aggressive/
advanced disease phenotype of poor prognosis.
Most of our understanding of the biology of ovarian cancer multicellular structures is based
on the premise that mono-dispersed ovarian cancer cells, when gathering together either by
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enforced gravity or prevention of adhesion, mimic the program of assembly followed by
ovarian cancer multicellular structures found within malignant effusions [63, 64]. Therefore,
it is of importance to define if ovarian cancer multicellular structures found in ascites represent
aggregation following shedding from solid tumors or, instead, are active products of disease
selection and critical drivers of disease advancement and prognosis (Fig.2).
While the presence of multicellular structures in ascites was reported over 25 years ago [57],
their biology has been studied using in vitro platforms and multicellular structures that were
forced to form from ovarian cancer cell lines by using either gravity or non-adherent condi‐
tions. We should investigate the pathogenic capacity of unforced, spontaneously arranged
ovarian cancer multicellular structures in vivo. If a key mechanism for ovarian cancer pro‐
gression takes place within the “liquid” component of the disease, then multicellular structures
may represent a druggable target. Developing therapeutic interventions to interrupt formation
of multicellular structures free-floating in the peritoneal fluid may be an efficient way of
interrupting disease advancement.
Figure 2. Proposed model for the role of ovarian cancer multicellular structures (MCS) in peritoneal carcinomatosis.
Selected cells from microscopic nodules with distinctive capacity to form MCS, adapt, survive, and grow in the perito‐
neal fluid developing irregular and organized spheroidal MCS that might evade chemotherapy and/or preserve ovari‐
an cancer initiating cells (CIC), leading to a feed-forward, chemo-resistant, and self-renewal recurrent seeding. MCS
committed to develop the solid component of the disease will adhere, disaggregate, migrate, and invade the mesothe‐
lial cell layer covering the surface of the peritoneum (maroon), and form foci that neo-vascularize and grow (green).
Other MCS might develop non-invasive nodules that amplify the cellularity within the “liquid” compartment causing
ascites. Blue: highly differentiated ovarian cancer cells. Pink: less differentiated ovarian cancer cells with self-renewal
capacity. Red: new blood vessels. Gray: extracellular matrix. Yellow: fibroblasts.
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9. Understanding dormancy after ”successful” standard of care (surgery
and chemotherapy)
Although most patients diagnosed with ovarian cancer undergo remission after optimal
surgical cytoreduction and platinum-taxane chemotherapy, microscopic foci of cells manage
to survive within the peritoneal cavity and recreate the illness. Recurrence develops a more
aggressive phenotype for which current therapies almost always fail (rev.in [1-6]). Thus,
understanding the biology of minimal residual disease is crucial in developing effective
therapies for ovarian cancer.
Figure 3. Hypothetical model of ovarian cancer dormancy after debulking surgery and platinum–taxane (PT) therapy,
relapse after chemotherapy-associated dormancy, and potential stages of the disease where therapeutic intervention is
envisioned. DFS, disease free survival; OS, overall survival. MRD, minimal residual disease.
Within the minimal residual disease, ovarian cancer cells are in a unique, subclinical, biological
stage termed dormancy. Long recognized in the clinic, dormancy describes a period of time that
can last many years between primary therapy and recurrence of metastatic disease (rev.in [65]).
In ovarian cancer, dormancy was reported to be represented by small, poorly vascularized
fibrotic nodules located on the surface of the peritoneum in patients undergoing second-look
surgery after front-line debulking operation and chemotherapy [66]. Dormant cancer cells are
usually defined as survivors of primary therapy likely containing drug-resistant, tumor-
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initiating cells. They are kept either in a status of cell cycle arrest (quiescence) or equilibrium
among proliferating and dying cells to preserve constant micro-tumor mass (rev.in [65]).
Attempts to eliminate dormant ovarian cancer cells with maintenance therapies have not been
efficient: they extend progression-free survival but not overall survival [67, 68].
It is important to investigate the magnitude and location of the disease still present following
an objective response to front-line therapy, and characterize the adaptive molecular reprog‐
ramming after chemotherapy leading to the dormant status of the cells comprising the minimal
residual disease (Fig.3). Chemotherapy-associated tumor dormancy and awakening from
dormancy likely have defined molecular signatures that can be unveiled by combined use of
currently available transcriptomic, proteomic, and epigenomic platforms that can be integrat‐
ed utilizing multipronged bioinformatic tools. Knowing the mechanism(s) ovarian cancer cells
utilize to achieve dormancy in the peritoneum and awake from it will provide two potential
avenues for intervention as follows: (1) perpetuation of the dormant status of the cancer; and/
or (2) interception of the awakening signal that causes disease relapse (Fig.3).
Whereas total elimination of ovarian cancer cells is the ideal goal, the alternative approach of
keeping ovarian cancer in a chronic dormant state is highly relevant as this would categorize
ovarian cancer patients with an objective response to front-line standard of care as having a
chronic manageable disease or “cancer without disease.”
10. Conclusions
Progresses made in the field of molecular oncology within the last decade have been remark‐
able. The use of RNA sequencing, micro RNA expression profiles, mutation analysis, shotgun
proteomics, reverse-phase protein arrays, and epigenomic platforms, together with novel
imaging tools, should be applied in uncovering the hidden secrets of ovarian cancer initiation
and progression, and in developing early diagnostic tools. Understanding the location and
molecular behavior of the abdominopelvic minimal residual disease after otherwise efficient
front-line chemotherapy should lead to the discovery of new molecular targets for disease
interception that can be exploited to prevent recurrence. We are at a point in time in which we
have a unique opportunity to utilize the vast state-of-the-art technological armamentarium
developed in the past decade to revisit the basic biology of peritoneal ovarian cancer and renew
hopes for bettering the prognosis of this deadly disease.
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